What happened in So-Young International’s (NASDAQ:SY) Q1 2026 earnings report?

So-Young International reported record first-quarter revenue as demand surged at its medical aesthetic clinics across China. Q1 2026 revenue rose 45.6% year over year to RMB432.8 million ($62.7 million). However, the company’s net loss widened because it spent heavily on opening and scaling more offline aesthetic centers.

Why did So-Young International (NASDAQ:SY) grow revenue so quickly in Q1 2026?

The biggest growth driver was So-Young’s offline aesthetic treatment business, which generated RMB282.4 million in revenue, up 185.8% year over year. The company said more users were converting from its online platform into paying customers at physical clinics. Strong customer traffic and rising treatment visits also helped accelerate growth.

Is So-Young International (NASDAQ:SY) profitable now?

No. Despite strong revenue growth, So-Young still reported a net loss attributable to shareholders of RMB49.2 million in Q1 2026, compared with a RMB34.6 million loss a year earlier. The larger loss was mainly tied to expansion costs, including marketing, staffing, and scaling its clinic network.

Why did So-Young International’s (NASDAQ:SY) losses increase even with strong sales growth?

So-Young is currently prioritizing expansion over near-term profitability. The company increased spending on localized marketing campaigns, hiring, and operating new aesthetic centers across mainland China. This strategy boosted revenue growth but also increased corporate overhead and operating expenses.

How strong is So-Young International’s (NASDAQ:SY) clinic business right now?

Operational metrics suggest the clinic business is gaining traction. Out of 54 branded aesthetic centers, 41 were net profitable during the quarter, while 48 generated positive operating cash flow individually. That suggests many locations are economically viable even though the overall company remains loss-making on a consolidated basis.

Image for illustrative purposes only. Not a real photo.

So-Young revenue rises 46% on strong aesthetic treatment demand

Written by Liezl GambePublished May. 22 2026Last Updated May. 22 2026

So-Young International (NASDAQ:SY) posted record first-quarter revenue that surpassed internal targets, propelled by a surge in consumer demand across its brick-and-mortar medical aesthetic centers, even as aggressive expansion spending weighed on near-term profitability.

The Beijing-based healthcare platform announced Friday that total revenue for the first quarter ended March 31, 2026, increased 45.6% year-over-year to RMB432.8 million ($62.7 million).

Growth was led by the company’s dedicated aesthetic treatment services division, which generated RMB282.4 million, reflecting a 185.8% increase from the prior-year period and beating management's previous guidance.

However, the rapid rollout of the company's offline clinic network dragged on the bottom line.

Net loss attributable to So-Young widened to RMB49.2 million ($7.1 million) for the quarter, compared to a net loss of RMB34.6 million in the first quarter of 2025.

Corporate overhead expanded alongside localized marketing campaigns and staff hiring required to support the larger operational footprint.

Operationally, customer traffic metrics showed significant acceleration, with verified treatment visits and total active users more than doubling compared to the same stretch last year.

Out of the company's 54 branded aesthetic centers currently operating throughout mainland China, 41 achieved net profitability during the quarter.

Furthermore, 48 of those locations generated positive individual operating cash flows, demonstrating viable unit economics despite the consolidated GAAP deficit.

Based on sustained transactional momentum carried into the spring, the company issued a strong forward-looking outlook for its offline business.

So-Young expects second-quarter aesthetic treatment revenue to grow by more than 112% year-over-year, banking on digital user acquisition channels to funnel more patients into its physical treatment network.